Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy

Oncogene

Volumn 25, Issue 7, 2006, Pages 981-989

  Goncalves A ^a,b,e   Esterni, B ^a   Bertucci, F ^a,b   Sauvan, R ^a   Chabannon, C ^a   Cubizolles, M ^c   Bardou, V J ^a   Houvenaegel, G ^a   Jacquemier, J ^a   Granjeaud, S ^d   Meng, X Y ^c   Fung, E T ^c   Birnbaum, D ^a   Maraninchi, D ^a,b   Viens, P ^a,b   Borg, J P ^a  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

^d Aix Marseille university   (France)

^e INSTITUT PAOLI CALMETTES   (France)

Author keywords

Breast cancer; Chemotherapy; Prognosis; proteomics; SELDI TOF MS; Serum profiling

Indexed keywords

ANTHRACYCLINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; COMPLEMENT COMPONENT C3A; HAPTOGLOBIN; TRANSFERRIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; LOG RANK TEST; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; RISK ASSESSMENT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; BLOOD PROTEINS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RECURRENCE;

EID: 33244488011     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209131     Document Type: Article

References (51)

1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. (2002a). Cancer Res 62: 3609-3614.
2. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. (2002b). Cancer Res 62: 3609-3614.
3. Ahmed N, Barker G, Oliva KT, Hoffmann P, Riley C, Reeve S et al. (2004). Br J Cancer 91: 129-140.
4. Antoniadis A, Lambert-Lacroix S, Leblanc F. (2003). Bioinformatics 19: 563-570.
5. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C et al. (2005). Cancer Res 65: 2170-2178.
6. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R et al. (2002). Hum Mol Genet 11: 863-872.
7. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT et al. (2004). Anticancer Res 24: 1031-1038.
8. Bonadonna G, Zambetti M, Valagussa P. (1995). JAMA 273: 542-547.
9. Carlevaro MF, Albini A, Ribatti D, Gentili C, Benelli R, Cermelli S et al. (1997). J Cell Biol 136: 1375-1384.
10. Cavanaugh PG, Jia L, Zou Y, Nicolson GL. (1999). Breast Cancer Res Treat 56: 203-217.
11. Cavanaugh PG, Nicolson GL. (1998). J Cell Physiol 174: 48-57.
12. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. (1993). J Clin Invest 91: 977-985.
13. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. (2003). J Clin Oncol 21: 1431-1439.
14. Clark EA, Golub TR, Lander ES, Hynes RO. (2000). Nature 406: 532-535.
15. Cox DR. (1972). J R Stat Soc [B] 34: 187-220.
16. De Kleijn DPV, Smeets MB, Kemmeren PPCW, Lim SK, van Middelaar BJ, Velema E et al. (2002). FASEB J 16: 1123-1125.
17. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G. (1997). Ann Oncol 8: 1075-1080.
18. Diamandis EP. (2004). J Natl Cancer Inst 96: 353-356.
19. EBCTCG (1998). Lancet 352: 930-942.
20. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. (1989). Cancer Res 49: 1996-2001.
21. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. (2001). Curr Opin Biotechnol 12: 65-69.
22. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY et al. (2005). Int J Cancer 115: 783-789.
23. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J. (2003). J Clin Oncol 21: 3357-3365.
24. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. (1999). Science 286: 531-537.
25. Heimann R, Hellman S. (2000). Eur J Cancer 36: 1631-1639.
26. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. (2003). J Clin Oncol 21: 976-983.
27. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL. (1993). J Cell Physiol 156: 212-217.
28. Kaplan EL, Meier P. (1958). J Am Stat Assoc 53: 457-481.
29. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S et al. (2004). Clin Cancer Res 10: 860-868.
30. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA et al. (2003). Proc Natl Assoc Sci 100: 12343-12348.
31. Kwak J-Y, Ma T-Z, Yoo M-J, Hee Choi B, Kim H-G, Kim S-R et al. (2004). Exp Hematol 32: 836-842.
32. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C et al. (2002). Proc Am Soc Clin Oncol 21: 36a (Abstract 141).
33. Nguyen DV, Rocke DM. (2002a). Bioinformatics 18: 1216-1226.
34. Nguyen DV, Rocke DM. (2002b). Bioinformatics 18: 39-50.
35. Nicolson GL, Cavanaugh PG, Inoue T. (1992). J Natl Cancer Inst Monogr 13: 153-161.
36. NIH (2001). J Natl Cancer Inst 93: 979-989.
37. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. (2004). N Engl J Med 351: 2817-2826.
38. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C et al. (2004). Hepatology 41: 40-47.
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Nature 406: 747-752.
40. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. (2002a). Lancet 359: 572-577.
41. Petricoin III EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA et al. (2002b). J Natl Cancer Inst 94: 1576-1578.
42. Pupa SM, Menard S, Forti S, Tagliabue E. (2002). J Cell Physiol 192: 259-267.
43. Rozanov DV, Savinov AY, Golubkov VS, Postnova TI, Remacle A, Tomlinson S et al. (2004). J Biol Chem 279: 46551-46557.
44. Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT et al. (2003). Proteomics 3: 601-609.
45. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M et al. (2003). The Lancet 362: 527-533.
46. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A et al. (2004). Lab Invest 84: 845-856.
47. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. (2002). N Engl J Med 347: 1999-2009.
48. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R et al. (2003). Breast Cancer Res 5: 57-58.
49. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D et al. (2003). Clin Breast Cancer 4: 203-209.
50. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack Jr BC et al. (2004). Clin Cancer Res 10: 1625-1632.
51. Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al. (2004). Cancer Res 64: 5882-5890.